Ra Capital Management buys $15,752,306 stake in Aquinox Pharmaceuticals Inc (AQXP)

Aquinox Pharmaceuticals Inc (AQXP) : Ra Capital Management scooped up 72,000 additional shares in Aquinox Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,691,977 shares of Aquinox Pharmaceuticals Inc which is valued at $15,752,306.Aquinox Pharmaceuticals Inc makes up approximately 1.83% of Ra Capital Management’s portfolio.

Other Hedge Funds, Including , Susquehanna International Group Llp added AQXP to its portfolio by purchasing 23,839 company shares during the most recent quarter which is valued at $221,941. Visium Asset Management Lp sold out all of its stake in AQXP during the most recent quarter. The investment firm sold 1,301,617 shares of AQXP which is valued $12,118,054. Perceptive Advisors sold out all of its stake in AQXP during the most recent quarter. The investment firm sold 59,600 shares of AQXP which is valued $554,876.Royce Associates Lp boosted its stake in AQXP in the latest quarter, The investment management firm added 86,455 additional shares and now holds a total of 182,622 shares of Aquinox Pharmaceuticals Inc which is valued at $1,692,906. Aquinox Pharmaceuticals Inc makes up approx 0.01% of Royce Associates Lp’s portfolio.

Aquinox Pharmaceuticals Inc opened for trading at $10.57 and hit $13.75 on the upside on Thursday, eventually ending the session at $12.24, with a gain of 15.25% or 1.62 points. The heightened volatility saw the trading volume jump to 26,53,509 shares. Company has a market cap of $211 M.

Aquinox Pharmaceuticals Inc. formerly Aquinox Pharmaceuticals (USA) Inc. is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1 which is a regulator of a cellular signaling pathway in immune cells known as the PI3K pathway. Its lead product candidate AQX-1125 is a small molecule activator of SHIP1 suitable for oral once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125 it is advancing through Phase II development in several initial indications. The Company operates in Vancouver British Columbia Canada.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *